Results 131 to 140 of about 45,696 (262)

Review of ceftazidime-avibactam for the treatment of infections caused by pseudomonas aeruginosa

, 2021
Pseudomonas aeruginosa is an opportunistic Gram-negative pathogen that causes a range of serious infections that are often challenging to treat, as this pathogen can express multiple resistance mechanisms, including multidrug-resistant (MDR) and ...
da Cunha, C.A., Irani, P., Baillon-Plot, N., Tawadrous, M., Daikos, G.L., Rossolini, G.M., Stone, G.G.   +6 more
core  

Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.

Journal of global antimicrobial resistance, 2021
Clinical experience with ceftazidime-avibactam (CAZ-AVI) for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-KP) infections is not well evaluated. The aim of this study was to assess its efficacy in a single-centre cohort of patients infected with CR-KP.We conducted a retrospective observational study of consecutive patients treated for
Jie, Gu, Jie, Xu, Ting-Ting, Zuo, Yan-Bin, Chen   +3 more
openaire   +1 more source

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against multidrug-resistant Klebsiella pneumoniae and Escherichia coli

, 2019
Background: Increasing resistance to broad-spectrum cephalosporin and carbapenem in Enterobacteriaceae makes it challenging to select appropriate antibiotics. There are limited treatment options for these pathogens.
이승철
core  

Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa

, 2017
Objectives: When tested in broth, avibactam reverses ceftazidime resistance in many Pseudomonas aeruginosa that express ESBLs. We examined whether similar reversal is observed against intracellular forms of P. aeruginosa.
Krause, K.M., Nichols, W. W., Muccioli, Giulio, Buyck, Julien, Van Bambeke, Françoise, Luyckx, C., Tulkens, Paul M.   +6 more
core   +1 more source

Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections

, 2017
Ceftazidime-avibactam is a novel cephalosporin–beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE).
Safia Kuriakose, Madeline King, Kenneth Biason, Jason C. Gallagher, Vanthida Huang, Julianne Gardner, Dorothy McCoy, Nicole Harrington, Lynette Richards, Claudine El-Beyrouty, Emily Heil, Tiffany Bias, Jon Hiles   +12 more
core   +1 more source

In-vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase

, 2015
Ceftazidime-avibactam is active against most Enterobacteriaceae isolates with KPC carbapenemases. We investigated whether this activity could be compromised by mutation.
Warner, Marina, Mustafa, Nazim, Livermore, David, Nichols, Wright W., Jamrozy, Dorota, Woodford, Neil, Mushtaq, Shazad   +6 more
core   +1 more source

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam

Background: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem resistant Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics.
Mithilesh Kumar Jha, Mukesh Kumar, Sunali, Maneesh Kumar, Nishant Ranjan   +4 more
core   +1 more source

Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers

, 2018
Objectives: Our objective was to develop population pharmacokinetic (PK) models for ceftazidime and avibactam in the plasma and epithelial lining fluid (ELF) of healthy volunteers and to compare ELF concentrations to plasma PK/pharmacodynamic (PD ...
Dimelow, R, Newell, P, MacPherson, M, Das, S, Wright, JG   +4 more
core   +1 more source

Diverse evolutionary trajectories of Klebsiella pneumoniae carbapenemase: unraveling the impact of amino acid substitutions on β-lactam susceptibility and the role of avibactam in driving resistance

mSystems
Klebsiella pneumoniae carbapenemases (KPCs) have evolved into over 245 distinct variants, with over one-third of variants exhibiting reduced susceptibility to ceftazidime-avibactam, while the underlying selection mechanisms remain elusive.
Jie Wei, Jinyu Huang, Chunhong Zou, Shimei Shen, Barry N. Kreiswirth, Ailong Huang, Shifeng Huang, Liang Chen, Deqiang Wang, Siqiang Niu   +9 more
doaj   +1 more source